AN EPITOME ON TUBERCULOSIS: A PHASE OF DRUG DISCOVERY TO NANOTECHNOLOGY

Abstract

Mycobacterium tuberculosis is a chronic infectious disease. It kills approximately 1.7 million people in the world and also has the highest risk of reactivation in the patients with latent infection. Relapse of the disease and drug resistance (MDR-TB/XDR-TB) are the key parameters of too complex tuberculosis therapy. Due to this varied failure treatment on this globe has asked the researchers to identify novel targets and to intercorrelate its mechanism of action. With an ascending growth of the disease and more specifically drug-resistance has signified its emergence for new anti-tuberculosis drugs. Thus, with the prior knowledge and applying it in the drug discovery has led a convincing opportunity for the modification of current inhibitors or to develop new drugs. With the re-arrangement of recognized scaffolds is applied in its core structure which may help in the improvement of bactericidal, pharmacokinetics and pharmacodynamics activities. Along with the surveys carried out, a large number of compounds are screened against Mycobacterium tuberculosis and can be helpful later in the computer databases. The present drug discovery should include an integrative analysis with computational databases. Nanomedicine also plays an important role in the management of the disease. The nano-sensors which help in the detection of infection rate have provoked its role for the rapid and short term diagnosis. Thus, with the current literature review it can be noted that interconnecting computational chemistry with the nanotechnology diagnosis can be helpful for short term therapy as well as lesser side effects.